| Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale G Colucci, V Gebbia, G Paoletti, F Giuliani, M Caruso, N Gebbia, ... Journal of Clinical Oncology 23 (22), 4866-4875, 2005 | 985 | 2005 |
| Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy A Ravaud, RJ Motzer, HS Pandha, DJ George, AJ Pantuck, A Patel, ... New england journal of medicine 375 (23), 2246-2254, 2016 | 790 | 2016 |
| Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ... The lancet oncology 18 (12), 1688-1700, 2017 | 641 | 2017 |
| Prevalence of malnutrition in patients at first medical oncology visit: the PreMiO study M Muscaritoli, S Lucia, A Farcomeni, V Lorusso, V Saracino, C Barone, ... Oncotarget 8 (45), 79884, 2017 | 392 | 2017 |
| Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 … G Colucci, R Labianca, F Di Costanzo, V Gebbia, G Cartenì, B Massidda, ... | 378 | 2010 |
| Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized … L Dogliotti, G Cartenì, S Siena, O Bertetto, A Martoni, A Bono, D Amadori, ... European urology 52 (1), 134-141, 2007 | 345 | 2007 |
| Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis G Di Lorenzo, R Autorino, G Bruni, G Carteni, E Ricevuto, M Tudini, ... Annals of oncology 20 (9), 1535-1542, 2009 | 236 | 2009 |
| Adjuvant sunitinib for high-risk renal cell carcinoma after nephrectomy: subgroup analyses and updated overall survival results RJ Motzer, A Ravaud, JJ Patard, HS Pandha, DJ George, A Patel, ... European urology 73 (1), 62-68, 2018 | 216 | 2018 |
| Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma ME Gore, C Szczylik, C Porta, S Bracarda, GA Bjarnason, S Oudard, ... British journal of cancer 113 (1), 12-19, 2015 | 200 | 2015 |
| Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1 … S De Placido, G Scambia, G Di Vagno, E Naglieri, AV Lombardi, ... Journal of clinical oncology 22 (13), 2635-2642, 2004 | 186 | 2004 |
| Association of systemic inflammation index and body mass index with survival in patients with renal cell cancer treated with nivolumab U De Giorgi, G Procopio, D Giannarelli, R Sabbatini, A Bearz, S Buti, ... Clinical Cancer Research 25 (13), 3839-3846, 2019 | 176 | 2019 |
| Sunitinib in metastatic renal cell carcinoma patients with brain metastases ME Gore, S Hariharan, C Porta, S Bracarda, R Hawkins, GA Bjarnason, ... Cancer 117 (3), 501-509, 2011 | 171 | 2011 |
| Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer G Di Lorenzo, G Cartenì, R Autorino, G Bruni, M Tudini, M Rizzo, M Aieta, ... Journal of Clinical Oncology 27 (27), 4469-4474, 2009 | 169 | 2009 |
| Malignant peritoneal mesothelioma—results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent G Carteni, C Manegold, GM Garcia, S Siena, CC Zielinski, D Amadori, ... Lung cancer 64 (2), 211-218, 2009 | 149 | 2009 |
| Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian … S Pignata, S De Placido, R Biamonte, G Scambia, G Di Vagno, G Colucci, ... BMC cancer 6, 1-7, 2006 | 147 | 2006 |
| Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial N Normanno, AM Rachiglio, M Lambiase, E Martinelli, F Fenizia, ... Annals of oncology 26 (8), 1710-1714, 2015 | 135 | 2015 |
| Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial F Ciardiello, N Normanno, E Maiello, E Martinelli, T Troiani, S Pisconti, ... Annals of oncology 25 (9), 1756-1761, 2014 | 133 | 2014 |
| Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the … E Verzoni, G Cartenì, E Cortesi, D Giannarelli, A De Giglio, R Sabbatini, ... Journal for immunotherapy of cancer 7, 1-9, 2019 | 124 | 2019 |
| Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis S Bracarda, R Iacovelli, L Boni, M Rizzo, L Derosa, M Rossi, L Galli, ... Annals of Oncology 26 (10), 2107-2113, 2015 | 124 | 2015 |
| Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo … F De Vita, F Giuliani, M Orditura, E Maiello, G Galizia, N Di Martino, ... Annals of oncology 18 (8), 1354-1358, 2007 | 115 | 2007 |
